enGene reports q2 results and cash position
- enGene Therapeutics (NASDAQ:ENGN) reported $285.2 million in cash, cash equivalents, and marketable securities as of April 30, 2026.
- The company reported a net loss of $30.2 million for the second quarter of 2026.
- Management plans to initiate a Biologics License Application (BLA) submission with the FDA in the second half of 2026.
enGene Therapeutics (NASDAQ:ENGN) announced its financial results for the second quarter ended April 30, 2026, alongside updates on its clinical development pipeline.
The company reported a net loss of $30.2 million for the quarter, compared to a $25.8 million net loss for the same period in 2025.
Total operating expenses reached $32 million for the quarter, driven by higher clinical costs for the LEGEND trial and preparation for upcoming regulatory submissions.
The company expects to maintain its current trajectory while preparing for a planned BLA submission with the FDA later this year, and following the announcement the enGene share price was unchanged at $10.15.
This clinical-stage company focuses on developing non-viral genetic medicines designed to address significant unmet needs in patient care.
enGene previously completed PPQ batch manufacturing to support its regulatory strategy and ongoing development efforts for its core therapeutic candidates.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
